Balaxi Pharmaceuticals Limited

NSEI:BALAXI Stock Report

Market Cap: ₹4.0b

Balaxi Pharmaceuticals Valuation

Is BALAXI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BALAXI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BALAXI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BALAXI's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BALAXI?

Key metric: As BALAXI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BALAXI. This is calculated by dividing BALAXI's market cap by their current earnings.
What is BALAXI's PE Ratio?
PE Ratio10.8x
Earnings₹355.97m
Market Cap₹4.02b

Price to Earnings Ratio vs Peers

How does BALAXI's PE Ratio compare to its peers?

The above table shows the PE ratio for BALAXI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average40.7x
QMSMEDI QMS Medical Allied Services
20xn/a₹2.0b
DENTALKART Vasa Denticity
59xn/a₹9.9b
MADHAVBAUG Vaidya Sane Ayurved Laboratories
37.6xn/a₹1.5b
REMUS Remus Pharmaceuticals
46.1xn/a₹13.9b
BALAXI Balaxi Pharmaceuticals
10.8xn/a₹4.0b

Price-To-Earnings vs Peers: BALAXI is good value based on its Price-To-Earnings Ratio (10.8x) compared to the peer average (40.7x).

Price to Earnings Ratio vs Industry

How does BALAXI's PE Ratio compare vs other companies in the IN Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
523696 Fortis Malar Hospitals
2.1xn/aUS$11.88m
542918 Gian Life Care
4.8xn/aUS$2.32m
No more companies available in this PE range
BALAXI 10.8xIndustry Avg. 42.6xNo. of Companies6PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BALAXI is good value based on its Price-To-Earnings Ratio (10.8x) compared to the Indian Healthcare industry average (42.6x).

Price to Earnings Ratio vs Fair Ratio

What is BALAXI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BALAXI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BALAXI's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Dr Lalchandani Labs

₹81.2m

Provides diagnostic and related healthcare tests and services in India.

541299

₹18.73

7D

4.1%

1Y

-46.5%

N G Industries

₹566.9m

Provides various healthcare services in India.

530897

₹169.20

7D

1.8%

1Y

4.4%

Yatharth Hospital & Trauma Care Services

₹52.0b

Owns and operates super-specialty hospitals in Delhi and Madhya Pradesh.

YATHARTH

₹605.95

7D

3.6%

1Y

49.8%